Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is currently conducting a study titled ‘A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%’. The study aims to evaluate the effectiveness of combining fianlimab with cemiplimab compared to cemiplimab alone in treating advanced NSCLC, focusing on treatment efficacy, side effects, and quality of life improvements.
The study tests two drugs: fianlimab, an anti-LAG-3 antibody, and cemiplimab, an anti-PD-1 antibody. These are administered as intravenous co-infusions every three weeks, with the goal of enhancing treatment outcomes for NSCLC patients.
This interventional study follows a randomized, parallel assignment model with quadruple masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide insights into the potential benefits of the drug combination.
The study began on March 14, 2023, with primary completion expected by August 29, 2025. The last update was submitted on August 29, 2025, indicating ongoing progress in the study.
For investors, this study could influence Regeneron’s market position, potentially boosting stock performance if results show significant benefits over existing treatments. The competitive landscape in NSCLC treatments is robust, and positive outcomes could enhance Regeneron’s standing in the industry.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.